Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Mattson

Showing results (171-180 of 190) with videos related to

Pageof 19
Sort By:
Bioorganic & Medicinal Chemistry Letters|March 18, 2011
Potential CRF1R PET imaging agents: N-fluoroalkyl-8-(6-methoxy-2-methylpyridin-3-yl)-2,7-dimethyl-N-alkylpyrazolo[1,5-a][1,3,5]triazin-4-aminesDmitry Zuev, Ronald J Mattson, Hong Huang, et al.
Nature Communications|March 29, 2012
Casein kinase 2 reverses tail-independent inactivation of kinesin-1Jing Xu, Babu J N Reddy, Preetha Anand, et al.
Seminars in Oncology|June 1, 1997
A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancerC Manegold, P Drings, J von Pawel, et al.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2005
Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancerE H Tan, A Szczesna, M Krzakowski, et al.
European Journal of Pharmacology|June 25, 2008
Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonistIldiko Antal-Zimanyi, Marc A Bruce, Karen L Leboulluec, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 1997
Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancerC Manegold, B Bergman, A Chemaissani, et al.
Bioorganic & Medicinal Chemistry Letters|April 13, 2013
Conformationally restricted homotryptamines. Part 6: indole-5-cycloalkyl methylamines as selective serotonin reuptake inhibitorsJonathan L Ditta, Derek J Denhart, Jeffrey A Deskus, et al.
Lung Cancer (Amsterdam, Netherlands)|November 24, 1999
Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancerW W ten Bokkel Huinink, B Bergman, A Chemaissani, et al.
Bioorganic & Medicinal Chemistry Letters|March 8, 2013
Potential CRF1R PET imaging agents: 1-fluoroalkylsubstituted 5-halo-3-(arylamino)pyrazin-2(1H)-onesDerek J Denhart, Dmitry Zuev, Jonathan L Ditta, et al.
Bioorganic & Medicinal Chemistry Letters|January 30, 2002
Dihydropyridine neuropeptide Y Y(1) receptor antagonistsGraham S Poindexter, Marc A Bruce, Karen L LeBoulluec, et al.
Pageof 19

Showing results (171-180 of 190) with videos related to

Sort By:
Pageof 19
Bioorganic & Medicinal Chemistry Letters|March 18, 2011
Potential CRF1R PET imaging agents: N-fluoroalkyl-8-(6-methoxy-2-methylpyridin-3-yl)-2,7-dimethyl-N-alkylpyrazolo[1,5-a][1,3,5]triazin-4-aminesDmitry Zuev, Ronald J Mattson, Hong Huang, et al.
Nature Communications|March 29, 2012
Casein kinase 2 reverses tail-independent inactivation of kinesin-1Jing Xu, Babu J N Reddy, Preetha Anand, et al.
Seminars in Oncology|June 1, 1997
A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancerC Manegold, P Drings, J von Pawel, et al.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2005
Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancerE H Tan, A Szczesna, M Krzakowski, et al.
European Journal of Pharmacology|June 25, 2008
Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonistIldiko Antal-Zimanyi, Marc A Bruce, Karen L Leboulluec, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 1997
Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancerC Manegold, B Bergman, A Chemaissani, et al.
Bioorganic & Medicinal Chemistry Letters|April 13, 2013
Conformationally restricted homotryptamines. Part 6: indole-5-cycloalkyl methylamines as selective serotonin reuptake inhibitorsJonathan L Ditta, Derek J Denhart, Jeffrey A Deskus, et al.
Lung Cancer (Amsterdam, Netherlands)|November 24, 1999
Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancerW W ten Bokkel Huinink, B Bergman, A Chemaissani, et al.
Bioorganic & Medicinal Chemistry Letters|March 8, 2013
Potential CRF1R PET imaging agents: 1-fluoroalkylsubstituted 5-halo-3-(arylamino)pyrazin-2(1H)-onesDerek J Denhart, Dmitry Zuev, Jonathan L Ditta, et al.
Bioorganic & Medicinal Chemistry Letters|January 30, 2002
Dihydropyridine neuropeptide Y Y(1) receptor antagonistsGraham S Poindexter, Marc A Bruce, Karen L LeBoulluec, et al.
Pageof 19